Cargando…
Evaluating cepharanthine analogues as natural drugs against SARS‐CoV‐2
Cepharanthine (CEP) is a natural biscoclaurine alkaloid of plant origin and was recently demonstrated to have anti‐severe acute respiratory syndrome coronavirus 2 (anti‐SARS‐CoV‐2) activity. In this study, we evaluated whether natural analogues of CEP may act as potential anti‐coronavirus disease 20...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727928/ https://www.ncbi.nlm.nih.gov/pubmed/34850606 http://dx.doi.org/10.1002/2211-5463.13337 |
_version_ | 1784626617334628352 |
---|---|
author | Hijikata, Atsushi Shionyu‐Mitsuyama, Clara Nakae, Setsu Shionyu, Masafumi Ota, Motonori Kanaya, Shigehiko Hirokawa, Takatsugu Nakajima, Shogo Watashi, Koichi Shirai, Tsuyoshi |
author_facet | Hijikata, Atsushi Shionyu‐Mitsuyama, Clara Nakae, Setsu Shionyu, Masafumi Ota, Motonori Kanaya, Shigehiko Hirokawa, Takatsugu Nakajima, Shogo Watashi, Koichi Shirai, Tsuyoshi |
author_sort | Hijikata, Atsushi |
collection | PubMed |
description | Cepharanthine (CEP) is a natural biscoclaurine alkaloid of plant origin and was recently demonstrated to have anti‐severe acute respiratory syndrome coronavirus 2 (anti‐SARS‐CoV‐2) activity. In this study, we evaluated whether natural analogues of CEP may act as potential anti‐coronavirus disease 2019 drugs. A total of 24 compounds resembling CEP were extracted from the KNApSAcK database, and their binding affinities to target proteins, including the spike protein and main protease of SARS‐CoV‐2, NPC1 and TPC2 in humans, were predicted via molecular docking simulations. Selected analogues were further evaluated by a cell‐based SARS‐CoV‐2 infection assay. In addition, the efficacies of CEP and its analogue tetrandrine were assessed. A comparison of the docking conformations of these compounds suggested that the diphenyl ester moiety of the molecules was a putative pharmacophore of the CEP analogues. |
format | Online Article Text |
id | pubmed-8727928 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87279282022-01-11 Evaluating cepharanthine analogues as natural drugs against SARS‐CoV‐2 Hijikata, Atsushi Shionyu‐Mitsuyama, Clara Nakae, Setsu Shionyu, Masafumi Ota, Motonori Kanaya, Shigehiko Hirokawa, Takatsugu Nakajima, Shogo Watashi, Koichi Shirai, Tsuyoshi FEBS Open Bio Research Articles Cepharanthine (CEP) is a natural biscoclaurine alkaloid of plant origin and was recently demonstrated to have anti‐severe acute respiratory syndrome coronavirus 2 (anti‐SARS‐CoV‐2) activity. In this study, we evaluated whether natural analogues of CEP may act as potential anti‐coronavirus disease 2019 drugs. A total of 24 compounds resembling CEP were extracted from the KNApSAcK database, and their binding affinities to target proteins, including the spike protein and main protease of SARS‐CoV‐2, NPC1 and TPC2 in humans, were predicted via molecular docking simulations. Selected analogues were further evaluated by a cell‐based SARS‐CoV‐2 infection assay. In addition, the efficacies of CEP and its analogue tetrandrine were assessed. A comparison of the docking conformations of these compounds suggested that the diphenyl ester moiety of the molecules was a putative pharmacophore of the CEP analogues. John Wiley and Sons Inc. 2021-12-09 /pmc/articles/PMC8727928/ /pubmed/34850606 http://dx.doi.org/10.1002/2211-5463.13337 Text en © 2021 The Authors. FEBS Open Bio published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Hijikata, Atsushi Shionyu‐Mitsuyama, Clara Nakae, Setsu Shionyu, Masafumi Ota, Motonori Kanaya, Shigehiko Hirokawa, Takatsugu Nakajima, Shogo Watashi, Koichi Shirai, Tsuyoshi Evaluating cepharanthine analogues as natural drugs against SARS‐CoV‐2 |
title | Evaluating cepharanthine analogues as natural drugs against SARS‐CoV‐2 |
title_full | Evaluating cepharanthine analogues as natural drugs against SARS‐CoV‐2 |
title_fullStr | Evaluating cepharanthine analogues as natural drugs against SARS‐CoV‐2 |
title_full_unstemmed | Evaluating cepharanthine analogues as natural drugs against SARS‐CoV‐2 |
title_short | Evaluating cepharanthine analogues as natural drugs against SARS‐CoV‐2 |
title_sort | evaluating cepharanthine analogues as natural drugs against sars‐cov‐2 |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727928/ https://www.ncbi.nlm.nih.gov/pubmed/34850606 http://dx.doi.org/10.1002/2211-5463.13337 |
work_keys_str_mv | AT hijikataatsushi evaluatingcepharanthineanaloguesasnaturaldrugsagainstsarscov2 AT shionyumitsuyamaclara evaluatingcepharanthineanaloguesasnaturaldrugsagainstsarscov2 AT nakaesetsu evaluatingcepharanthineanaloguesasnaturaldrugsagainstsarscov2 AT shionyumasafumi evaluatingcepharanthineanaloguesasnaturaldrugsagainstsarscov2 AT otamotonori evaluatingcepharanthineanaloguesasnaturaldrugsagainstsarscov2 AT kanayashigehiko evaluatingcepharanthineanaloguesasnaturaldrugsagainstsarscov2 AT hirokawatakatsugu evaluatingcepharanthineanaloguesasnaturaldrugsagainstsarscov2 AT nakajimashogo evaluatingcepharanthineanaloguesasnaturaldrugsagainstsarscov2 AT watashikoichi evaluatingcepharanthineanaloguesasnaturaldrugsagainstsarscov2 AT shiraitsuyoshi evaluatingcepharanthineanaloguesasnaturaldrugsagainstsarscov2 |